Please login to the form below

Not currently logged in

GSK wins approval for anti-PD-1 antibody Jemperli in endometrial cancer

AnaptysBio earns a $20m milestone payment on approval after originally developing the drug

British pharma company GlaxoSmithKline (GSK) has received US approval for its PD-1 inhibitor Jemperli for the treatment of endometrial cancer.

The Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, following an FDA-approved test.

Cells that are mismatch repair (MMR) deficient often have many DNA mutations and are commonly found in colorectal, gastrointestinal and endometrial cancer.

Endometrial cancer has the highest rate of dMMR among solid tumour types, with approximately 25% bearing this biomarker.

The accelerated approval is based on results from the dMMR endometrial cancer cohort of the GARNET trial, evaluating the drug as a monotherapy treatment for these patients.

The primary endpoints in this trial were overall response rate (ORR) and duration of response (DOR), as assessed by blinded independent central review (BICR).

In this trial, among the 71 evaluable patients with advanced or recurrent dMMR endometrial cancer, the ORR was 42.3%, with a complete response rate of 12.7% and partial response (PR) of 29.6%.

For the responding patients, 93.3% demonstrated a DOR of six months or more, with the median duration of response not reached after a median follow-up of 14.1 months.

GSK acquired Jemperli as part of its $5.1bn acquisition of cancer specialist Tesaro, although the drug was initially developed by AnaptysBio.

Following this FDA approval, AnaptysBio has earned a $20m milestone payment. Last year, the company also received milestone payments of $10m and $5m, respectively, for the FDA’s and European Medicines Agency’s (EMA) acceptances of filings for Jemperli.

“Unfortunately, as many as 60,000 women are diagnosed with endometrial cancer in the US each year and these women currently have limited treatment options if their disease progresses on or after first-line therapy,” said Hal Barron, chief scientific officer and president of R&D at GSK.

“Today’s approval of Jemperli by the FDA has the potential to transform the treatment landscape for these women and demonstrates our continued commitment to helping patients with gynaecologic cancers,” he added.

GSK is also completing ongoing evaluations of Jemperli for patients with advanced dMMR solid tumours, as well as in earlier treatment lines for endometrial cancer.

Article by
Lucy Parsons

23rd April 2021

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....
Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....